Abstract
The passive transfer of antibodies and vaccination procedures against p185, the erbB2/neu oncoprotein, are approaches being explored for treatment of human breast cancer. We now report the possibility of using the erbB2/neu gene as an immunogen. This study demonstrates that intramuscular or intradermal injections of rat neuNT full-length DNA into mice generate anti-p185 autoantibodies. Anti-p185 polyclonals were also shown to bind the homologous human receptor ErbB2 and to stain specimens of breast adenocarcinoma from both neu-transgenic mice and humans. Further, in vitro assays demonstrated that anti-p185 IgG (probably dependent on CD4+ Th1) were able to inhibit human SKBR3 tumour cell growth and to mediate their lysis by natural killer cells. The continuous presence of circulating neu autoantibodies in mice did not cause any discernible toxic effects on normal tissues expressing low levels of self-antigen, even after 1 year.
Similar content being viewed by others
Author information
Authors and Affiliations
Additional information
Received: 29 August 1996 / Accepted: 31 October 1996
Rights and permissions
About this article
Cite this article
Concetti, A., Amici, A., Petrelli, C. et al. Autoantibody to p185erbB2/neu oncoprotein by vaccination with xenogenic DNA. Cancer Immunol Immunother 43, 307–315 (1997). https://doi.org/10.1007/s002620050338
Issue Date:
DOI: https://doi.org/10.1007/s002620050338